Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2025)

Benitec Biopharma has reported Accumulated Expenses over the past 7 years, most recently at $483000.0 for Q4 2025.

  • Quarterly results put Accumulated Expenses at $483000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $483000.0 (changed N/A YoY), and the annual figure for FY2025 was $426000.0, down 10.32%.
  • Accumulated Expenses reached $483000.0 in Q4 2025 per BNTC's latest filing, up from $463000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $523000.0 in Q4 2023 and bottomed at $231000.0 in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $427500.0 (2023), compared with a mean of $411666.7.
  • The largest annual shift saw Accumulated Expenses surged 54.55% in 2022 before it decreased 10.32% in 2025.
  • Over 5 years, Accumulated Expenses stood at $321000.0 in 2021, then rose by 23.36% to $396000.0 in 2022, then surged by 32.07% to $523000.0 in 2023, then dropped by 5.35% to $495000.0 in 2024, then decreased by 2.42% to $483000.0 in 2025.
  • Business Quant data shows Accumulated Expenses for BNTC at $483000.0 in Q4 2025, $463000.0 in Q3 2025, and $426000.0 in Q2 2025.